Interesting topics Rick although I don't think you have a good handle on it, nor do I. I think from the good results we see, there is NO cross resistance to other treatments and side effects are mostly a result of the individual drug. As to front-line VS salvage it gets more intriguing. The two obvious (to me) questions is how SGEN-35 will interact with other front-line agents and CD30 expression differences. As to the former, it would be best to schedule RX to enhance the chances for maximum cell kill. This could be a big advantage for 35 being an immunotoxin. It gives another mechanism of action for cell kill, so theoretically there can be expectations for a better outcome than standard therapy when the two are scheduled together for maximum cell kill. As for CD30 expression, I wonder if there is a difference between new and relapsed patients? Often times a primary tumor is polyclonal (or mixed phenotype) and relapsed tumors more uniform. Not sure if this is true for CD30 expression but if it is, that could affect outcome of frontline VS relapsed therapy. Anybody have insight on that?